The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: Potential for breast cancer therapeutics

Apoptosis

Volumn 17, Issue 2, 2012, Pages 164-173

  Brosseau, Carole ^a   Colston, Kay ^a   Dalgleish, Angus George ^a   Galustian, Christine ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Lenalidomide; Sensitivity; Vitamin D

Indexed keywords

CALCITRIOL; LENALIDOMIDE; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 12A; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CALCITRIOL; THALIDOMIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862486754     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-011-0670-5     Document Type: Article

References (33)

1. Pinette KV, Yee YK, Amegadzie BY, Nagpal S (2003) Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 3:193-204
2. Colston KW, Berger U, Wilson P, Hadcocks L, Naeem I, Earl HM, Coombes RC (1988) Mammary gland 1, 25-dihydroxyvitamin D3 receptor content during pregnancy and lactation. Mol Cell Endocrinol 60:15-22
3. Zinser GM, Welsh J (2004) Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol 18:2208-2223 (Pubitemid 39215251)
4. Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J (1998) Expression of 1, 25-dihydroxy vitamin D3 receptor in breast carcinoma. J Histochem Cytochem 46:1335-1337 (Pubitemid 28487754)
5. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrath J (2002) Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J 34:35-40
6. Guyton KZ, Kensler TW, Posner GH (2001) Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 41:421-442 (Pubitemid 32385894)
7. Colston KW, Hansen CM (2002) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45-59 (Pubitemid 34298363)
8. Verlinden L, Verstuyf A, Convents R, Marcelis S, Van CM, Bouillon R (1998) Action of 1, 25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142:57-65 (Pubitemid 28438279)
9. Mathiasen IS, Lademann U, Jaattela M (1999) Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59:4848-4856 (Pubitemid 29472887)
10. Trump DL, Muindi J, Fakih MA, Yu WD, Johnson CS (2006) Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res 26:2551-2556 (Pubitemid 44155534)
11. Guyton KZ, Kensler TW, Posner GH (2003) Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 61:227-238 (Pubitemid 37259932)
12. Byrne B, Welsh J (2007) Identification of novel mediators of Vitamin D signaling and 1, 25(OH)2D3 resistance in mammary cells. J Steroid Biochem Mol Biol 103:703-707 (Pubitemid 46401345)
13. Welsh J (2007) Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 22(Supp 2):86-90
14. Colston KW, Chander SK, Mackay AG, Coombes RC (1992) Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702
15. Kemmis CM, Welsh J (2008) Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 105:980-988
16. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525-4530 (Pubitemid 34627223)
17. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24:22-32
18. Galustian C, Dalgleish A (2009) Lenalidomide: a novel anti-cancer drug with multiple modalities. Expert Opin Pharmacother 10:125-133
19. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033-1045
20. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2009) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101:803-812
21. Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X, Xu J (2008) Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol In Vitro 22:1749-1753
22. Koh DW, Dawson TM, Dawson VL (2005) Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 52:5-14 (Pubitemid 40725595)
23. Hansen CM, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L (2001) MCF-7/VD(R): a new vitamin D resistant cell line. J Cell Biochem 82:422-436 (Pubitemid 32734141)
24. Manion MK, Fry J, Schwartz PS, Hockenbery DM (2006) Smallmolecule inhibitors of Bcl-2. Curr Opin Investig Drugs 7:1077-1084
25. Manion MK, Hockenbery DM (2003) Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2:S105-S114
26. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW, Rosenberg SH, Elmore SW (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14:3268-3277
27. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428
28. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM (2009) Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113:4403-4413
29. Vogler M, Dinsdale D, Dyer MJ, Cohen GM (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360-367
30. Liu W, Nizar S, Dalgleish A (2010) Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med Oncol 27:430-433
31. Fryer R, Galustian C, Dalgleish AG (2009) Activity of the MAPK signalling cascade correlates to gemcitabine sensitivity in pancreatic cancer cells. Eur J Cancer Suppl 7:91
32. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG (2009) A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 27:5156
33. Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2011) Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate, in press